Skip to main content
SpringerLink
Log in

Noninfectious Intermediate, Posterior, and Panuveitis

  • Chapter
  • First Online:
Uveitis

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

Abstract

Classification systems exist in uveitis based on the clinical course (acute, chronic or recurrent), etiology (infectious or noninfectious), laterality (unilateral or bilateral), histology (granulomatous or nongranulomatous), and primary anatomic location of inflammation. Classification based on the primary location of inflammation is critical in establishing a differential diagnosis and thereby treatment approach. Classification as intermediate, posterior, and panuveitis is based on the Standardization of Uveitis Nomenclature (SUN) working group definitions. Based on their criteria, intermediate uveitis refers to ocular inflammatory disease in which the primary site of inflammation is the middle of the eye. This includes the anterior vitreous cavity, posterior ciliary body, peripheral retina, and pars plana. Posterior uveitis refers to those entities in which the primary site of inflammation is the retina and/or choroid. Panuveitis indicates that the anterior segment, vitreous cavity, and retina/choroid are all involved in the disease process. While many uveitic entities may present as one or more of the aforementioned anatomic classifications, this chapter stratifies various diseases based on their typical location of involvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–16.

    Article  PubMed  Google Scholar 

  2. Lai WW, Pulido JS. Intermediate uveitis. Ophthalmol Clin N Am. 2002;15:309–17.

    Article  Google Scholar 

  3. Lin P, Loh AR, Margolis TP, et al. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010;117:585–90.

    Article  PubMed  Google Scholar 

  4. Lin P, Tessler HH, Goldstein DA. Family history of inflammatory bowel disease in patients with idiopathic ocular inflammation. Am J Ophthalmol. 2006;141:1097–104.

    Article  PubMed  Google Scholar 

  5. Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in veterans affairs medical Centers of the Pacific Northwest. Am J Ophthalmol. 2008;146:890–6, e8.

    Article  PubMed  Google Scholar 

  6. Donaldson MJ, Pulido JS, Herman DC, et al. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007;144:812–7.

    Article  PubMed  Google Scholar 

  7. Vidovic-Valentincic N, Kraut A, Hawlina M, et al. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol. 2009;93:477–80.

    Article  CAS  PubMed  Google Scholar 

  8. Althaus C, Sundmacher R. Intermediate uveitis: epidemiology, age and sex distribution. Dev Ophthalmol. 1992;23:9–14.

    Article  CAS  PubMed  Google Scholar 

  9. Eichenbaum JW, Friedman AH, Mamelok AE. A clinical and histopathological review of intermediate uveitis (“pars planitis”). Bull N Y Acad Med. 1988;64:164–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Pederson JE, Kenyon KR, Green WR, et al. Pathology of pars planitis. Am J Ophthalmol. 1978;86:762–74.

    Article  CAS  PubMed  Google Scholar 

  11. Malalis JF, Bhat P, Shapiro M, Goldstein DA. Retinoschisis in pars Planitis. Ocul Immunol Inflamm. 2017;25(3):344–8.

    Article  PubMed  Google Scholar 

  12. Lai JC, Stinnett SS, Jaffe GJ. B-scan ultrasonography for the detection of macular thickening. Am J Ophthalmol. 2003;136:55–61.

    Article  PubMed  Google Scholar 

  13. Campbell JP, Leder HA, Sepah YJ, et al. Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol. 2012;154(5):908–11, e2.

    Article  PubMed  Google Scholar 

  14. Leder HA, Campbell JP, Sepah YJ, et al. Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect. 2013;3(1):30.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Campbell JP, Beardsley RM, Palejwala NV, et al. Peripheral vascular leakage in uveitis: clinical and angiographic findings. Ophthalmology. 2015;122(6):1269–70.

    Article  PubMed  Google Scholar 

  16. Thomas AS, Redd T, Campbell JP, et al. The impact and implication of peripheral vascular leakage in uveitis. Ocul Immunol Inflamm. 2017;16:1–7.

    Google Scholar 

  17. Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology. 1999;106:594–9.

    Article  CAS  PubMed  Google Scholar 

  18. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med. 2000;343:898–904.

    Article  CAS  PubMed  Google Scholar 

  19. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet. 2001;357:1576–82.

    Article  CAS  PubMed  Google Scholar 

  20. Lin P, Jaffe GJ. Intermediate uveitis. In: Schachat AP, Wilkinson CP, Hinton DR, et al., editors. Ryan’s retina. 6th ed: Elsevier Inc. New York; 2018.

    Chapter  Google Scholar 

  21. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967–75.

    Article  Google Scholar 

  22. Chieh JJ, Carlson AN, Jaffe GJ. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. Am J Ophthalmol. 2008;146:589–94.

    Article  CAS  PubMed  Google Scholar 

  23. Malone PE, Herndon LW, Muir KW, et al. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Am J Ophthalmol. 2010;149:800–6, e1.

    Article  CAS  PubMed  Google Scholar 

  24. Ghosn CR, Li Y, Orilla WC, et al. Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:2917–23.

    Article  CAS  PubMed  Google Scholar 

  25. Jaffe GJ, Lin P, Keenan RT, Ashton P, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940–8.

    Article  PubMed  Google Scholar 

  26. Okinami S, Sunakawa M, Arai I, et al. Treatment of pars planitis with cryotherapy. Ophthalmologica. 1991;202:180–6.

    Article  CAS  PubMed  Google Scholar 

  27. Dugel PU, Rao NA, Ozler S, et al. Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids: a preliminary study. Ophthalmology. 1992;99:1535–41.

    Article  CAS  PubMed  Google Scholar 

  28. Verbraeken H. Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results. Graefes Arch Clin Exp Ophthalmol. 1996;234:288–93.

    Article  CAS  PubMed  Google Scholar 

  29. Tranos P, Scott R, Zambarakji H, et al. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study. Br J Ophthalmol. 2006;90:1107–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140:1096–105.

    Article  PubMed  Google Scholar 

  31. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–98, e1.

    Article  PubMed  Google Scholar 

  32. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–32.

    Article  PubMed  Google Scholar 

  33. Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–43.

    Article  CAS  PubMed  Google Scholar 

  34. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–92.

    Article  CAS  PubMed  Google Scholar 

  35. Li SY, Birnbaum AD, Goldstein DA. Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm. 2010;18:475–81.

    Article  CAS  PubMed  Google Scholar 

  36. Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50(6):519–41.

    Article  PubMed  Google Scholar 

  37. Priem HA, Kijlstra A, Noens L, et al. HLA typing in birdshot chorioretinopathy. Am J Ophthalmol. 1988;105(2):182–5.

    Article  CAS  PubMed  Google Scholar 

  38. Priem HA, Oosterhuis JA. Birdshot chorioretinopathy: clinical characteristics and evolution. Br J Ophthalmol. 1988;72(9):646–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Soubrane G, Bokobza R, Coscas G. Late developing lesions in birdshot retinochoroidopathy. Am J Ophthalmol. 1990;109(2):204–10.

    Article  CAS  PubMed  Google Scholar 

  40. Böni C, Thorne JE, Spaide RF, et al. Choroidal findings in eyes with birdshot chorioretinitis using enhanced-depth optical coherence tomography. Invest Ophthalmol Vis Sci. 2016;57(9):591–9.

    Article  CAS  Google Scholar 

  41. Thomas AS, Hatef AL, Stinnett SS, Keenan RT, Jaffe GJ. Perivascular thickening on optical coherence tomography as a marker of inflammation in birdshot retinochoroiditis. Retina. 2019;39:956–63.

    Article  PubMed  Google Scholar 

  42. Shao EH, Menezo V, Taylor SR. Birdshot chorioretinopathy. Curr Opin Ophthalmol. 2014;25(6):488–94.

    Article  PubMed  Google Scholar 

  43. Böni C, Thorne JE, Spaide RF, et al. Fundus autofluorescence findings in eyes with birdshot chorioretinitis. Invest Ophthalmol Vis Sci. 2017;58(10):4015–25.

    Article  PubMed  Google Scholar 

  44. Calvo-río V, Blanco R, Santos-gómez M, et al. Efficacy of anti-IL6-receptor Tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review. Ocul Immunol Inflamm. 2016;25:1–6.

    Google Scholar 

  45. Jampol LM, Wiredu A. MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many? Retina. 1995;15(5):373–8.

    Article  CAS  PubMed  Google Scholar 

  46. Essex RW, Wong J, Jampol LM, et al. Idiopathic multifocal choroiditis: a comment on present and past nomenclature. Retina. 2013;33(1):1–4.

    Article  PubMed  Google Scholar 

  47. Spaide RF, Goldberg N, Freund KB. Redefining multifocal choroiditis and panuveitis and punctate inner choroidopathy through multimodal imaging. Retina. 2013;33(7):1315–24.

    Article  PubMed  Google Scholar 

  48. Fung AT, Pal S, Yannuzzi NA, et al. Multifocal choroiditis without panuveitis: clinical characteristics and progression. Retina. 2014;34(1):98–107.

    Article  PubMed  Google Scholar 

  49. Deutsch TA, Tessler HH. Inflammatory pseudohistoplasmosis. Ann Ophthalmol. 1985;17(8):461–5.

    CAS  PubMed  Google Scholar 

  50. Kedhar SR, Thorne JE, Wittenberg S, et al. Multifocal choroiditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina. 2007;27(9):1174–9.

    Article  PubMed  Google Scholar 

  51. Buerk BM, Rabb MF, Jampol LM. Peripapillary subretinal fibrosis: a characteristic finding of multifocal choroiditis and panuveitis. Retina. 2005;25(2):228–9.

    Article  PubMed  Google Scholar 

  52. Brown J, Folk JC. Current controversies in the white dot syndromes. Multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ocul Immunol Inflamm. 1998;6(2):125–7.

    Article  CAS  PubMed  Google Scholar 

  53. Thorne JE, Wittenberg S, Jabs DA, et al. Multifocal choroiditis with panuveitis: incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006;113(12):2310–6.

    Article  PubMed  Google Scholar 

  54. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (Avastin) and ranibizumab (Lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29(1):8–12.

    Article  PubMed  Google Scholar 

  55. Parodi MB, Iacono P, Kontadakis DS, et al. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. Arch Ophthalmol. 2010;128(9):1100–3.

    Article  PubMed  Google Scholar 

  56. Vossmerbaeumer U, Spandau UH, von Baltz S, et al. Intravitreal bevacizumab for choroidal neovascularisation secondary to punctate inner choroidopathy. Clin Exp Ophthalmol. 2008;36(3):292–4.

    Article  PubMed  Google Scholar 

  57. Brown J, Folk JC, Reddy CV, et al. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103(7):1100–5.

    Article  PubMed  Google Scholar 

  58. Essex RW, Wong J, Fraser-Bell S, et al. Punctate inner choroidopathy: clinical features and outcomes. Arch Ophthalmol. 2010;128(8):982–7.

    Article  PubMed  Google Scholar 

  59. Leung TG, Moradi A, Liu D, et al. Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina. 2014;34(8):1666–74.

    Article  PubMed  Google Scholar 

  60. Jampol LM, Sieving PA, Pugh D, et al. Multiple evanescent white dot syndrome. I. Clinical findings. Arch Ophthalmol. 1984;102(5):671–4.

    Article  CAS  PubMed  Google Scholar 

  61. Olitsky SE. Multiple evanescent white-dot syndrome in a 10-year-old child. J Pediatr Ophthalmol Strabismus. 1998;35(5):288–9.

    CAS  PubMed  Google Scholar 

  62. Lim JI, Kokame GT, Douglas JP. Multiple evanescent white dot syndrome in older patients. Am J Ophthalmol. 1999;127(6):725–8.

    Article  CAS  PubMed  Google Scholar 

  63. Shelsta HN, Rao RR, Bhatt HK, et al. Atypical presentations of multiple evanescent white dot syndrome without white dots: a case series. Retina. 2011;31(5):973–6.

    Article  PubMed  Google Scholar 

  64. Luttrull JK, Marmor MF, Nanda M. Progressive confluent circumpapillary multiple evanescent white-dot syndrome. Am J Ophthalmol. 1999;128(3):378–80.

    Article  CAS  PubMed  Google Scholar 

  65. Daniele S, Daniele C, Ferri C. Association of peripapillary scars with lesions characteristic of multiple evanescent white-dot syndrome. Ophthalmologica. 1995;209(4):217–9.

    Article  CAS  PubMed  Google Scholar 

  66. Wyhinny GJ, Jackson JL, Jampol LM, et al. Subretinal neovascularization following multiple evanescent white-dot syndrome. Arch Ophthalmol. 1990;108(10):1384–5.

    Article  CAS  PubMed  Google Scholar 

  67. McCollum CJ, Kimble JA. Peripapillary subretinal neovascularization associated with multiple evanescent white-dot syndrome. Arch Ophthalmol. 1992;110(1):13–4.

    Article  CAS  PubMed  Google Scholar 

  68. Marsiglia M, Gallego-Pinazo R, Cunha de Souza E, et al. Expanded clinical spectrum of multiple evanescent white dot syndrome with multimodal imaging. Retina. 2016;36(1):64–74.

    Article  PubMed  Google Scholar 

  69. Dell’Omo R, Mantovani A, Wong R, et al. Natural evolution of fundus autofluorescence findings in multiple evanescent white dot syndrome: a long-term follow-up. Retina. 2010;30(9):1479–87.

    Article  PubMed  Google Scholar 

  70. Furino C, Boscia F, Cardascia N, et al. Fundus autofluorescence and multiple evanescent white dot syndrome. Retina. 2009;29(1):60–3.

    Article  PubMed  Google Scholar 

  71. Hamed LM, Glaser JS, Gass JD, et al. Protracted enlargement of the blind spot in multiple evanescent white dot syndrome. Arch Ophthalmol. 1989;107(2):194–8.

    Article  CAS  PubMed  Google Scholar 

  72. Chen D, Martidis A, Baumal CR. Transient multifocal electroretinogram dysfunction in multiple evanescent white dot syndrome. Ophthalmic Surg Lasers. 2002;33(3):246–9.

    CAS  PubMed  Google Scholar 

  73. Dodwell DG, Jampol LM, Rosenberg M, et al. Optic nerve involvement associated with the multiple evanescent white-dot syndrome. Ophthalmology. 1990;97(7):862–8.

    Article  CAS  PubMed  Google Scholar 

  74. Battaglia Parodi M, Iacono P, Verbraak FD, et al. Antivascular endothelial growth factors for inflammatory chorioretinal disorders. Dev Ophthalmol. 2010;46:84–95.

    Article  PubMed  Google Scholar 

  75. Tsai L, Jampol LM, Pollock SC, et al. Chronic recurrent multiple evanescent white dot syndrome. Retina. 1994;14(2):160–3.

    Article  CAS  PubMed  Google Scholar 

  76. Figueroa MS, Ciancas E, Mompean B, et al. Treatment of multiple evanescent white dot syndrome with cyclosporine. Eur J Ophthalmol. 2001;11(1):86–8.

    Article  CAS  PubMed  Google Scholar 

  77. Thomas BC, Jacobi C, Korporal M, et al. Ocular outcome and frequency of neurological manifestations in patients with acute posterior multifocal placoid pigment epitheliopathy (APMPPE). J Ophthalmic Inflamm Infect. 2012;2(3):125–31.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Pagnoux C, Thorne C, Mandelcorn ED, et al. CNS involvement in acute posterior multifocal placoid pigment epitheliopathy. Can J Neurol Sci. 2011;38(3):526–8.

    Article  PubMed  Google Scholar 

  79. Althaus C, Unsöld R, Figge C, et al. Cerebral complications in acute posterior multifocal placoid pigment epitheliopathy. Ger J Ophthalmol. 1993;2(3):150–4.

    CAS  PubMed  Google Scholar 

  80. Stoll G, Reiners K, Schwartz A, et al. Acute posterior multifocal placoid pigment epitheliopathy with cerebral involvement. J Neurol Neurosurg Psychiatry. 1991;54(1):77–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Abu El-Asrar AM, Aljazairy AH. Acute posterior multifocal placoid pigment epitheliopathy with retinal vasculitis and papillitis. Eye (Lond). 2002;16(5):642–4.

    Article  CAS  Google Scholar 

  82. De Souza S, Aslanides IM, Altomare F. Acute posterior multifocal placoid pigment epitheliopathy associated with retinal vasculitis, neovascularization and subhyaloid hemorrhage. Can J Ophthalmol. 1999;34(6):343–5.

    PubMed  Google Scholar 

  83. Bird AC, Hamilton AM. Placoid pigment epitheliopathy: presenting with bilateral serous retinal detachment. Br J Ophthalmol. 1972;56(12):881–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Garg S, Jampol LM. Macular serous detachment in acute posterior multifocal placoid pigment epitheliopathy. Retina. 2004;24(4):650–1.

    Article  PubMed  Google Scholar 

  85. Birnbaum AD, Blair MP, Tessler HH, et al. Subretinal fluid in acute posterior multifocal placoid pigment epitheliopathy. Retina. 2010;30(5):810–4.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Bowie EM, Sletten KR, Kayser DL, et al. Acute posterior multifocal placoid pigment epitheliopathy and choroidal neovascularization. Retina. 2005;25(3):362–4.

    Article  PubMed  Google Scholar 

  87. Lofoco G, Ciucci F, Bardocci A, et al. Optical coherence tomography findings in a case of acute multifocal posterior placoid pigment epitheliopathy (AMPPPE). Eur J Ophthalmol. 2005;15(1):143–7.

    Article  PubMed  Google Scholar 

  88. Scheufele TA, Witkin AJ, Schocket LS, et al. Photoreceptor atrophy in acute posterior multifocal placoid pigment epitheliopathy demonstrated by optical coherence tomography. Retina. 2005;25(8):1109–12.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Gass JD. Acute posterior multifocal placoid pigment epitheliopathy. Arch Ophthalmol. 1968;80(2):177–85.

    Article  CAS  PubMed  Google Scholar 

  90. Howe LJ, Woon H, Graham EM, et al. Choroidal hypoperfusion in acute posterior multifocal placoid pigment epitheliopathy: an indocyanine green angiography study. Ophthalmology. 1995;102(5):790–8.

    Article  CAS  PubMed  Google Scholar 

  91. Spaide RF. Autofluorescence imaging of acute posterior multifocal placoid pigment epitheliopathy. Retina. 2006;26(4):479–82.

    PubMed  Google Scholar 

  92. Cohen LM, Munk MR, Goldstein DA, Jampol LM. Acute, posterior multifocal placoid pigment epitheliopathy: a case of 11 recurrences over 15 years. Retin Cases Brief Rep. 2015;9(3):226–30.

    Article  PubMed  Google Scholar 

  93. Fiore T, Iaccheri B, Androudi S, et al. Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina. 2009;29(7):994–1001.

    Article  PubMed  Google Scholar 

  94. Mavrakanas N, Mendrinos E, Tabatabay C, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy. Acta Ophthalmol. 2010;88(2):e54–5.

    Article  PubMed  Google Scholar 

  95. Erkkilä H, Laatikainen L, Jokinen E. Immunological studies on serpiginous choroiditis. Graefes Arch Clin Exp Ophthalmol. 1982;219(3):131–4.

    Article  PubMed  Google Scholar 

  96. Chisholm IH, Gass JD, Hutton WL. The late stage of serpiginous (geographic) choroiditis. Am J Ophthalmol. 1976;82(3):343–51.

    Article  CAS  PubMed  Google Scholar 

  97. Lim WK, Buggage RR, Nussenblatt RB. Serpiginous choroiditis. Surv Ophthalmol. 2005;50(3):231–44.

    Article  PubMed  Google Scholar 

  98. Lee DK, Suhler EB, Augustin W, et al. Serpiginous choroidopathy presenting as choroidal neovascularisation. Br J Ophthalmol. 2003;87(9):1184–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Wu JS, Lewis H, Fine SL, et al. Clinicopathologic findings in a patient with serpiginous choroiditis and treated choroidal neovascularization. Retina. 1989;9(4):292–301.

    Article  CAS  PubMed  Google Scholar 

  100. Laatikainen L, Erkkilä H. Subretinal and disc neovascularization in serpiginous choroiditis. Br J Ophthalmol. 1982;66(5):326–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Friberg TR. Serpiginous choroiditis with branch vein occlusion and bilateral periphlebitis: case report. Arch Ophthalmol. 1988;106(5):585–6.

    Article  CAS  PubMed  Google Scholar 

  102. Steinmetz RL, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. Retina. 1991;11(4):412–5.

    Article  CAS  PubMed  Google Scholar 

  103. Hardy RA, Schatz H. Macular geographic helicoid choroidopathy. Arch Ophthalmol. 1987;105(9):1237–42.

    Article  CAS  PubMed  Google Scholar 

  104. Mansour AM, Jampol LM, Packo KH. Macular serpiginous choroiditis. Retina. 1988;8(2):125–31.

    Article  CAS  PubMed  Google Scholar 

  105. van Velthoven ME, Ongkosuwito JV, Verbraak FD, et al. Combined en-face optical coherence tomography and confocal ophthalmoscopy findings in active multifocal and serpiginous chorioretinitis. Am J Ophthalmol. 2006;141(5):972–5.

    Article  PubMed  Google Scholar 

  106. Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, et al. The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol. 2007;91(12):1680–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Punjabi OS, Rich R, Davis JL, et al. Imaging serpiginous choroidopathy with spectral domain optical coherence tomography. Ophthalmic Surg Lasers Imaging. 2008;39(Suppl. 4):S95–8.

    PubMed  Google Scholar 

  108. Cardillo Piccolino F, Grosso A, Savini E. Fundus autofluorescence in serpiginous choroiditis. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):179–85.

    Article  PubMed  Google Scholar 

  109. Arantes TE, Matos K, Garcia CR, et al. Fundus autofluorescence and spectral domain optical coherence tomography in recurrent serpiginous choroiditis: case report. Ocul Immunol Inflamm. 2011;19(1):39–41.

    Article  PubMed  Google Scholar 

  110. Giovannini A, Mariotti C, Ripa E, et al. Indocyanine green angiographic findings in serpiginous choroidopathy. Br J Ophthalmol. 1996;80(6):536–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Yeh S, Forooghian F, Wong WT, et al. Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol. 2010;128(1):46–56.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Carreño E, Portero A, Herreras JM, et al. Assesment of fundus autofluorescence in serpiginous and serpiginous-like choroidopathy. Eye (Lond). 2012;26(9):1232–6.

    Article  Google Scholar 

  113. Nazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. Surv Ophthalmol. 2013;58(3):203–32.

    Article  PubMed  Google Scholar 

  114. Golchet PR, Jampol LM, Wilson D, et al. Persistent placoid maculopathy: a new clinical entity. Trans Am Ophthalmol Soc. 2006;104:108–20.

    PubMed  PubMed Central  Google Scholar 

  115. Akpek EK, Baltatzis S, Yang J, et al. Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm. 2001;9(3):153–67.

    Article  CAS  PubMed  Google Scholar 

  116. Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98(6):944–51.

    Article  CAS  PubMed  Google Scholar 

  117. Araujo AA, Wells AP, Dick AD, et al. Early treatment with cyclosporine in serpiginous choroidopathy maintains remission and good visual outcome. Br J Ophthalmol. 2000;84(9):979–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Leznoff A, Shea M, Binkley KE, et al. Cyclosporine in the treatment of nonmicrobial inflammatory ophthalmic disease. Can J Ophthalmol. 1992;27(6):302–6.

    CAS  PubMed  Google Scholar 

  119. Seth RK, Gaudio PA. Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. Ocul Immunol Inflamm. 2008;16(3):103–5.

    Article  PubMed  Google Scholar 

  120. Akpek EK, Jabs DA, Tessler HH, et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002;109(8):1506–13.

    Article  PubMed  Google Scholar 

  121. Christmas NJ, Oh KT, Oh DM, et al. Long-term follow-up of patients with serpiginous choroiditis. Retina. 2002;22(5):550–6.

    Article  PubMed  Google Scholar 

  122. Jones BE, Jampol LM, Yannuzzi LA, et al. Relentless placoid chorioretinitis: a new entity or an unusual variant of serpiginous chorioretinitis? Arch Ophthalmol. 2000;118(7):931–8.

    CAS  PubMed  Google Scholar 

  123. Jyotirmay B, Jafferji SS, Sudharshan S, et al. Clinical profile, treatment, and visual outcome of ampiginous choroiditis. Ocul Immunol Inflamm. 2010;18(1):46–51.

    Article  PubMed  Google Scholar 

  124. Amer R, Florescu T. Optical coherence tomography in relentless placoid chorioretinitis. Clin Exp Ophthalmol. 2008;36(4):388–90.

    Article  PubMed  Google Scholar 

  125. Veronese C, Marcheggiani EB, Tassi F, et al. Early autofluorescence findings of relentless placoid chorioretinitis. Retina. 2014;34(3):625–7.

    Article  PubMed  Google Scholar 

  126. Yeh S, Lew JC, Wong WT, et al. Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil. Arch Ophthalmol. 2009;127(3):341–3.

    Article  PubMed  Google Scholar 

  127. Saito S, Saito W, Saito M, et al. Acute zonal occult outer retinopathy in Japanese patients: clinical features, visual function, and factors affecting visual function. PLoS One. 2015;10(4):e0125133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Mrejen S, Khan S, Gallego-Pinazo R, et al. Acute zonal occult uter retinopathy: a classification based on multimodal imaging. JAMA Ophthalmol. 2014;132(9):1089–98.

    Article  PubMed  Google Scholar 

  129. Shifera AS, Pennesi ME, Yang P, Lin P. Ultra-wide-field fundus autofluorescence findings in patients with acute zonal occult outer retinopathy. Retina. 2017;37(6):1104–19.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Cohen SYM, Jampol LMM. Choroidal neovascularization in peripapillary acute zonal occult outer retinopathy. Retin Cases Brief Rep. 2007;1(4):220–2.

    Article  PubMed  Google Scholar 

  131. Spaide RF, Koizumi H, Freund KB. Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy-complex diseases. Am J Ophthalmol. 2008;146(1):111–20.

    Article  PubMed  Google Scholar 

  132. Fujiwara T, Imamura Y, Giovinazzo VJ, et al. Fundus autofluorescence and optical coherence tomographic findings in acute zonal occult outer retinopathy. Retina. 2010;30(8):1206–16.

    Article  PubMed  Google Scholar 

  133. Gass JD, Agarwal A, Scott IU. Acute zonal occult outer retinopathy: a long-term follow-up study. Am J Ophthalmol. 2002;134(3):329–39.

    Article  PubMed  Google Scholar 

  134. Nakao S, Kaizu Y, Yoshida S, et al. Spontaneous remission of acute zonal occult outer retinopathy: follow-up using adaptive optics scanning laser ophthalmoscopy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):839–43.

    Article  PubMed  Google Scholar 

  135. Chen SN, Yang CH, Yang CM. Systemic corticosteroids therapy in the management of acute zonal occult outer retinopathy. J Ophthalmol. 2015;2015:793026.

    PubMed  PubMed Central  Google Scholar 

  136. Mahajan VB, Stone EM. Patients with an acute zonal occult outer retinopathy-like illness rapidly improve with valacyclovir treatment. Am J Ophthalmol. 2010;150(4):511–8.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Hoang QV, Gallego-Pinazo R, Yannuzzi LA. Long-term follow-up of acute zonal occult outer retinopathy. Retina. 2013;33(7):1325–7.

    Article  PubMed  Google Scholar 

  138. Turbeville SD, Cowan LD, Gass JD. Acute macular neuroretinopathy: a review of the literature. Surv Ophthalmol. 2003;48(1):1–11.

    Article  PubMed  Google Scholar 

  139. Munk MR, Jampol LM, Cunha Souza E, et al. New associations of classic acute macular neuroretinopathy. Br J Ophthalmol. 2016;100(3):389–94.

    Article  PubMed  Google Scholar 

  140. Fawzi AA, Pappuru RR, Sarraf D, et al. Acute macular neuroretinopathy: long-term insights revealed by multimodal imaging. Retina. 2012;32(8):1500–13.

    Article  PubMed  Google Scholar 

  141. Baumüller S, Holz FG. Early spectral-domain optical coherence tomography findings in acute macular neuroretinopathy. Retina. 2012;32(2):409–10.

    Article  PubMed  Google Scholar 

  142. Affortit AS, Lazrak Z, Leze RH, et al. En face spectral domain optical coherence tomography in a case of bilateral acute macular neuroretinopathy. Retina. 2015;35(5):1049–50.

    Article  PubMed  Google Scholar 

  143. Krill AE, Deutman AF. Acute retinal pigment epitheliitus. Am J Ophthalmol. 1972;74(2):193–205.

    Article  CAS  PubMed  Google Scholar 

  144. Iu LPL, Lee R, Fan MCY, Lam WC, Chang RT, Wong IYH. Serial spectral-domain optical coherence tomography findings in acute retinal pigment Epitheliitis and the correlation to visual acuity. Ophthalmology. 2017;124(6):903–9.

    Article  PubMed  Google Scholar 

  145. Baillif S, Wolff B, Paoli V, Gastaud P, Mauget-faÿsse M. Retinal fluorescein and indocyanine green angiography and spectral-domain optical coherence tomography findings in acute retinal pigment epitheliitis. Retina. 2011;31(6):1156–63.

    Article  PubMed  Google Scholar 

  146. Ushiyama O, Ushiyama K, Koarada S, et al. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2000;59:705–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Coppeto JR. Retinopathy and systemic lupus erythematosus. Arch Ophthalmol. 1984;102:1748–9.

    Article  CAS  PubMed  Google Scholar 

  148. Jabs DA, Fine SL, Hochberg MC, et al. Severe retinal vasoocclusive disease in systemic lupus erythematous. Arch Ophthalmol. 1986;104:558–63.

    Article  CAS  PubMed  Google Scholar 

  149. Asherson RA, Merry P, Acheson JF, et al. Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the “primary” antiphospholipid syndrome. Ann Rheum Dis. 1989;48:358–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Graham EM, Spalton DJ, Barnard RO, et al. Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology. 1985;92:444–8.

    Article  CAS  PubMed  Google Scholar 

  151. Jabs DA, Hanneken AM, Schachat AP, et al. Choroidopathy in systemic lupus erythematosus. Arch Ophthalmol. 1988;106:230–4.

    Article  CAS  PubMed  Google Scholar 

  152. Thomas AS, Lin P. Ocular manifestations of inflammatory bowel disease. Curr Opin Ophthalmol. 2016;27(6):552–60.

    Article  PubMed  Google Scholar 

  153. Jarius S, Neumayer B, Wandinger KP, et al. Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci. 2009;285:259–61.

    Article  CAS  PubMed  Google Scholar 

  154. Magro CM, Poe JC, Lubow M, Susac JO. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol. 2011;136:903–12.

    Article  CAS  PubMed  Google Scholar 

  155. Dörr J, Krautwald S, Wildemann B, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9(6):307–16.

    Article  PubMed  Google Scholar 

  156. Buelens T, Herode L, Nubourgh I, Caspers L, Willermain F, Postelmans L. Central retinal artery occlusion and Susac syndrome: a case report. Retin Cases Brief Rep. 2014;8(3):187–92.

    Article  PubMed  Google Scholar 

  157. Haider AS, Viswanathan D, Williams D, Davies P. Paracentral acute middle maculopathy in Susac syndrome. Retin Cases Brief Rep. 2017;. Epub ahead of print.

    Google Scholar 

  158. Rennebohm RM, Asdaghi N, Srivastava S, Gertner E. Guidelines for treatment of Susac syndrome—an update. Int J Stroke. 2018:1747493017751737. Epub ahead of print.

    Google Scholar 

  159. Rennebohm RM, Susac JO. Treatment of Susac’s syndrome. J Neurol Sci. 2007;257(1–2):215–20.

    Article  PubMed  Google Scholar 

  160. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234–41.

    Article  CAS  PubMed  Google Scholar 

  161. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon. 2009;55:649–60.

    Article  PubMed  Google Scholar 

  162. Tachibana T, Iwai K, Takemura T. Malignant respiratory-digestive fistulas. Curr Opin Pulm Med. 2010;16:465–71.

    Article  CAS  PubMed  Google Scholar 

  163. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1∗1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73:720–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Jamilloux Y, Kodjikian L, Broussolle C, et al. Sarcoidosis and uveitis. Autoimmun Rev. 2014;13:840–9.

    Article  PubMed  Google Scholar 

  165. Henderly DE, Genstler AJ, Smith RE, et al. Changing patterns of uveitis. Am J Ophthalmol. 1987;103:131–6.

    Article  CAS  PubMed  Google Scholar 

  166. Rosenbaum JT. Uveitis. An internist’s view. Arch Intern Med. 1989;149:1173–6.

    Article  CAS  PubMed  Google Scholar 

  167. James DG. Ocular sarcoidosis. Ann N Y Acad Sci. 1986;465:551–63.

    Article  CAS  PubMed  Google Scholar 

  168. Collison JM, Miller NR, Green WR. Involvement of orbital tissues by sarcoid. Am J Ophthalmol. 1986;102:302–7.

    Article  CAS  PubMed  Google Scholar 

  169. Derosa AJ, Margo CE, Orlick ME. Hemorrhagic retinopathy as the presenting manifestation of sarcoidosis. Retina. 1995;15(5):422–7.

    Article  CAS  PubMed  Google Scholar 

  170. Chen L, Xu G. Extensive choroidal infiltrates in choroidal biopsy proven ocular sarcoidosis. Retin Cases Brief Rep. 2013;7(1):69–70.

    Article  PubMed  Google Scholar 

  171. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102:297–301.

    Article  CAS  PubMed  Google Scholar 

  172. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS). Ocul Immunol Inflamm. 2009;17(3):160–9.

    Article  CAS  PubMed  Google Scholar 

  173. Invernizzi A, Mapelli C, Viola F, et al. Choroidal granulomas visualized by enhanced depth imaging optical coherence tomography. Retina. 2015;35(3):525–31.

    Article  PubMed  Google Scholar 

  174. Matsuo T, Itami M, Shiraga F. Choroidopathy in patients with sarcoidosis observed by simultaneous indocyanine green and fluorescein angiography. Retina. 2000;20(1):16–21.

    Article  CAS  PubMed  Google Scholar 

  175. Wolfensberger TJ, Herbort CP. Indocyanine green angiographic features in ocular sarcoidosis. Ophthalmology. 1999;106(2):285–9.

    Article  CAS  PubMed  Google Scholar 

  176. Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):95–101.

    CAS  PubMed  Google Scholar 

  177. Hosoya S, Kataoka M, Nakata Y, et al. Clinical features of 125 patients with sarcoidosis: Okayama University Hospital review of a recent 10-year period. Acta Med Okayama. 1992;46(1):31–6.

    CAS  PubMed  Google Scholar 

  178. Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol. 2007;51(2):121–6.

    Article  PubMed  Google Scholar 

  179. Maña J, Teirstein AS, Mendelson DS, Padilla ML, Depalo LR. Excessive thoracic computed tomographic scanning in sarcoidosis. Thorax. 1995;50(12):1264–6.

    Article  PubMed  PubMed Central  Google Scholar 

  180. Pakhale SS, Unruh H, Tan L, Sharma S. Has mediastinoscopy still a role in suspected stage I sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2006;23(1):66–9.

    PubMed  Google Scholar 

  181. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–23.

    Article  PubMed  Google Scholar 

  182. Wakefield D, Zierhut M. Controversy: ocular sarcoidosis. Ocul Immunol Inflamm. 2010;18:5–9.

    Article  PubMed  Google Scholar 

  183. Agrawal R, Gonzalez-Lopez JJ, Meier F, et al. Ocular and systemic features of sarcoidosis and correlation with the International Workshop for Ocular Sarcoidosis diagnostic criteria. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(3):237–45.

    PubMed  Google Scholar 

  184. Kojima K, Maruyama K, Inaba T, et al. The CD4/CD8 ratio in vitreous fluid is of high diagnostic value in sarcoidosis. Ophthalmology. 2012;119(11):2386–92.

    Article  PubMed  Google Scholar 

  185. Dev S, Mccallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106(1):111–8.

    Article  CAS  PubMed  Google Scholar 

  186. Deuter CME, Doycheva D, Stuebiger N, et al. Mycophenolate sodium for immunosuppressive treatment in uveitis. Ocul Immunol Inflamm. 2009;17:415–9.

    Article  CAS  PubMed  Google Scholar 

  187. Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–61, e10.

    Article  CAS  PubMed  Google Scholar 

  188. Karma A, Huhti E, Poukkula A. Course and outcome of ocular sarcoidosis. Am J Ophthalmol. 1988;106:467–72.

    Article  CAS  PubMed  Google Scholar 

  189. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 1996;103:1846–53.

    Article  CAS  PubMed  Google Scholar 

  190. Miserocchi E, Modorati G, Di Matteo F, et al. Visual outcome in ocular sarcoidosis: retrospective evaluation of risk factors. Eur J Ophthalmol. 2011;21(6):802–10.

    Article  PubMed  Google Scholar 

  191. Davatchi F, Chams-davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  192. De Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.

    Article  CAS  PubMed  Google Scholar 

  193. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The international criteria for Behçet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.

    Article  Google Scholar 

  194. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behcet's disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579–82.

    Article  PubMed  PubMed Central  Google Scholar 

  195. Kang HM, Lee SC. Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):1001–8.

    Article  PubMed  Google Scholar 

  196. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med. 1990;322(5):281–5.

    Article  CAS  PubMed  Google Scholar 

  197. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–74.

    Article  CAS  PubMed  Google Scholar 

  198. Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res. 2010;62(12):1733–8.

    Article  CAS  Google Scholar 

  199. Benitez-del-castillo JM, Martinez-de-la-casa JM, Pato-cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye. 2005;19(8):841–5.

    Article  CAS  PubMed  Google Scholar 

  200. Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014;5(3):112–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Alibaz-oner F, Sawalha AH, Direskeneli H. Management of Behçet’s disease. Curr Opin Rheumatol. 2018;30(3):238–42.

    Article  CAS  PubMed  Google Scholar 

  202. Weisz JM, Holland GN, Roer LN, et al. Association between Vogt–Koyanagi–Harada syndrome and HLA-DR1 and DR4 in Hispanic patients living in Southern California. Ophthalmology. 1995;102:1012–5.

    Article  CAS  PubMed  Google Scholar 

  203. Arellanes-Garcia L, Bautista N, More P, et al. HLA-DR is strongly associated with Vogt–Koyanagi–Harada disease in Mexican mestizo patients. Ocul Immunol Inflamm. 1998;6:93–100.

    Article  CAS  PubMed  Google Scholar 

  204. Kawano Y, Tawara A, Nishioka Y, et al. Ultrasound biomicroscopic analysis of transient shallow anterior chamber in Vogt–Koyanagi–Harada syndrome. Am J Ophthalmol. 1996;121:720–3.

    Article  CAS  PubMed  Google Scholar 

  205. Yamamoto N, Naito K. Annular choroidal detachment in patients with Vogt–Koyanagi–Harada disease. Graefes Arch Clin Exp Ophthalmol. 2004;242:355–8.

    Article  PubMed  Google Scholar 

  206. Rao NA, Gupta A, Dustin L, et al. Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology. 2010;117(3):591–9, 599.e1.

    Article  PubMed  Google Scholar 

  207. Vasconcelos-santos DV, Sohn EH, Sadda S, Rao NA. Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings. Retina. 2010;30(1):33–41.

    Article  PubMed  PubMed Central  Google Scholar 

  208. Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int Ophthalmol. 2007;27(2–3):173–82.

    Article  PubMed  Google Scholar 

  209. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–52.

    Article  CAS  PubMed  Google Scholar 

  210. Galor A, Davis JL, Flynn HW, et al. Sympathetic ophthalmia: incidence of ocular complications and vision loss in the sympathizing eye. Am J Ophthalmol. 2009;148(5):704–10, e2.

    Article  PubMed  Google Scholar 

  211. Davis JL, Mittal KK, Freidlin V, et al. HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology. 1990;97(9):1137–42.

    Article  CAS  PubMed  Google Scholar 

  212. Lai T, Chan R, Chan C, Lam D. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye. 2009;23(3):543–8.

    Article  CAS  PubMed  Google Scholar 

  213. Khalifa Y, Loh AR, Nisha R, et al. Fluocinolone acetonide intravitreal implants in Vogt–Koyanagi–Harada disease. Ocul Immunol Inflamm. 2009;17:431–3.

    Article  PubMed  Google Scholar 

  214. Paredes I, Ahmed M, Foster C. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14(2):87–90.

    Article  CAS  PubMed  Google Scholar 

  215. Kim S, Yu H. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15(5):381–7.

    Article  CAS  PubMed  Google Scholar 

  216. Kondo Y, Fukuda K, Suzuki K, et al. Chronic noninfectious uveitis associated with Vogt–Koyanagi–Harada disease treated with lowdose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56:104–6.

    Article  PubMed  Google Scholar 

  217. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt–Koyanagi–Harada syndrome. Ocul Immunol Inflamm. 2008;16:167–71.

    Article  CAS  PubMed  Google Scholar 

  218. Bykhovskaya I, Thorne JE, Kempen JH, Dunn JP, Jabs DA. Vogt-Koyanagi-Harada disease: clinical outcomes. Am J Ophthalmol. 2005;140(4):674–8.

    Article  PubMed  Google Scholar 

  219. Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al. Prognostic factors for clinical outcomes in patients with Vogt–Koyanagi–Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2013;91:486–93.

    Article  CAS  Google Scholar 

  220. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68(6):835–53.

    Article  CAS  PubMed  Google Scholar 

  221. Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16(11):1589–99.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma. Surv Ophthalmol. 2014;59(5):503–16.

    Article  PubMed  Google Scholar 

  223. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina. 2011;31(3):435–40.

    Article  CAS  PubMed  Google Scholar 

  224. Dean JM, Novak MA, Chan CC, et al. Tumor detachments of the retinal pigment epithelium in ocular/central nervous system lymphoma. Retina. 1996;16(1):47–56.

    Article  CAS  PubMed  Google Scholar 

  225. Gass JD, Trattler HL. Retinal artery obstruction and atheromas associated with non-Hodgkin’s large cell lymphoma (reticulum cell sarcoma). Arch Ophthalmol. 1991;109(8):1134–9.

    Article  CAS  PubMed  Google Scholar 

  226. Freeman LN, Schachat AP, Knox DL, et al. Clinical features, laboratory investigations, and survival in ocular reticulum cell sarcoma. Ophthalmology. 1987;94(12):1631–9.

    Article  CAS  PubMed  Google Scholar 

  227. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina. 2009;29(2):129–32.

    Article  PubMed  Google Scholar 

  228. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109(9):1709–16.

    Article  PubMed  Google Scholar 

  229. Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol. 2012;1(3):1.

    Article  PubMed  PubMed Central  Google Scholar 

  230. Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98(1):99–103.

    Article  PubMed  Google Scholar 

  231. Fishburne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115(9):1152–6.

    Article  CAS  PubMed  Google Scholar 

  232. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92(3):383–8.

    Article  CAS  PubMed  Google Scholar 

  233. Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology. 2008;71(17):1355–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tennessee Retina, Nashville, TN, USA

    Akshay S. Thomas

Authors
  1. Akshay S. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akshay S. Thomas .

Editor information

Editors and Affiliations

  1. Casey Eye Institute Oregon Health & Science University, Portland, OR, USA

    Phoebe Lin

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Thomas, A.S. (2020). Noninfectious Intermediate, Posterior, and Panuveitis. In: Lin, P. (eds) Uveitis . Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-15-0331-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0331-3_3

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0330-6

  • Online ISBN: 978-981-15-0331-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation